Neulasta (Pegfilgrastim) - Drug Interactions, Contraindications, Overdosage, etc

DRUG INTERACTIONS

NEULASTA drug label information in our database does not contain a dedicated section on drug interactions. Please check subsections of WARNINGS AND PRECAUTIONS as well as other sources.

OVERDOSAGE

The maximum amount of Neulasta^® that can be safely administered in single or multiple doses has not been determined. Single subcutaneous doses of 300 mcg/kg have been administered to 8 healthy volunteers and 3 patients with non‑small cell lung cancer without serious adverse effects. These patients experienced a mean maximum ANC of 55 x 10⁹/L, with a corresponding mean maximum WBC of 67 x 10⁹/L. The absolute maximum ANC observed was 96 x 10⁹/L with a corresponding absolute maximum WBC observed of 120 x 10⁹/L. The duration of leukocytosis ranged from 6 to 13 days. Leukapheresis should be considered in the management of symptomatic individuals.

CONTRAINDICATIONS

Neulasta^® is contraindicated in patients with known hypersensitivity to E coli‑ derived proteins‚ pegfilgrastim‚ Filgrastim, or any other component of the product.

REFERENCES

1. Morstyn G, Dexter T, Foote M. Filgrastim (r‑metHuG‑CSF) in clinical practice. 2nd ed. 1998;3:51‑71.
2. Valerius T, Elsasser D, Repp R, et al. HLA Class‑II antibodies recruit G‑CSF activated neutrophils for treatment of B‑cell malignancies. Leukemia and Lymphoma. 1997;26, 261‑269.
3. Heil G, Hoelzer D, Sanz MA, et al. A randomized, double‑blind, placebo‑controlled, phase III study of Filgrastim in remission induction and consolidation therapy for adults with de novo Acute Myeloid Leukemia. Blood. 1997;90:4710‑4718.

Manufactured by:

Amgen Manufacturing, Limited, a subsidiary of Amgen Inc.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

© 2002-2006 Amgen Inc. All rights reserved.

3;v6.1